首页 | 本学科首页   官方微博 | 高级检索  
     


SARS-CoV-2 Circulation during the First Year of the Pandemic: A Seroprevalence Study from January to December 2020 in Tuscany,Italy
Authors:Serena Marchi  Gianvito Lanave  Michele Camero  Francesca Dapporto  Alessandro Manenti  Linda Benincasa  Angela Acciavatti  Giulio Brogi  Simonetta Viviani  Emanuele Montomoli  Claudia Maria Trombetta
Affiliation:1.Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy; (S.V.); (E.M.); (C.M.T.);2.Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy; (G.L.); (M.C.);3.VisMederi Srl, 53100 Siena, Italy; (F.D.); (A.M.);4.VisMederi Research Srl, 53100 Siena, Italy;5.NeoMedica Srl, 53100 Siena, Italy; (A.A.); (G.B.)
Abstract:Italy was the second country affected by the SARS-CoV-2 pandemic; the virus spread mainly in Northern Italy with a subsequent diffusion to the center and southern part of the country. In this study, we aimed to assess the prevalence of antibodies against SARS-CoV-2 in the general population of the Siena province in the Tuscany region (Central Italy) during 2020. A total of 2480 serum samples collected from January to December 2020 were tested for IgM and IgG antibodies against SARS-CoV-2 by a commercial ELISA. Positive and borderline samples were further tested for the presence of anti-receptor-binding domain (RBD) IgM and IgG antibodies by an in-house ELISA and by a micro-neutralization assay. Out of the 2480 samples tested by the commercial ELISA, 81 (3.3%) were found to be positive or borderline for IgG and 58 (2.3%) for IgM in a total of 133 samples (5.4%) found to be positive or borderline for at least one antibody class. When the commercial ELISA and in-house ELISA/micro-neutralization assay results were combined, 26 samples (1.0%) were positive for RBD IgG, 11 (0.4%) for RBD IgM, and 23 (0.9%) for a neutralizing antibody. An increase in seroprevalence was observed during the year 2020, especially from the end of summer, consistent with the routine epidemiological surveillance of COVID-19 cases.
Keywords:SARS-CoV-2   Italy   seroprevalence
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号